Obesity And Metabolic Disorders
ENTXEntera Bio LtdCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for OPK-88006 (GLP-1/Glucagon Agonist) in Obesity And Metabolic Disorders. The expected timing is based on the latest available company guidance and may change.
11/14/25:- Minipig PK data for OPK-88006 reported; IND submission for oral OXM planned for H1 2026. 03/27/26:- ENDO 2025 PK/PD showed human-comparable exposure; injectable Ph1 data expected Q4 2026 to trigger oral tablet Ph1. 05/08/26:- EB618 oral OXM tablet NHP pharmacokinetic data submitted to ENDO2026; OPKO collaboration funding earmarked through early 2027. 05/28/26:- ENDO 2026 session presents EB618 non-human primate PK-PD results on June 13, 2026. 06/16/26:- ENDO 2026 EB618 NHP PK/PD showed robust bioavailability and glucose lowering. Injectable Ph1 data expected Q4 2026. 08/07/26:- EB618 NHP data support development, and OPKO Phase 1 SAD/MAD data are expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.